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Background
Psychotic experiences may emerge in more severe cases of
common mental disorders (CMD). Previous work identified that
30% of patients treated by mental health services in primary
healthcare, specifically the Improving Access to Psychological
Therapies (IAPT) programme in England, reported psychotic
experiences, began treatment with more severe CMD and were
less likely to reach recovery.
Aims
To replicate our previous assessment of psychotic experiences
in the IAPT programme using a more sensitive threshold and
determine its impact on the prevalence of psychotic experience
and likelihood of recovery. Additionally, to compare recovery
rates between patients with and without psychotic experiences
at the end of therapy.
Method
The Community Assessment of Psychic Experiences (CAPE-P15)
with a cut-off of 1.30 was used to determine the prevalence of
psychotic experiences. Recovery rates were determined using
measures collected in the IAPT programme for depression (PHQ-
9) and anxiety (GAD-7). Multi-group growth models estimated
improvement trajectories.
Results
In total, 2042 patients with CMD completed the CAPE-P15. The
mean age was 39.8. The prevalence of psychotic experiences
was 18% higher when using a lower threshold. The recovery rate
for patients with psychotic experiences was lower (36%) than for
those without (64%). Despite sharing similar improvement
trajectories, the higher initial severity of CMD among patients
with psychotic experiences impeded likelihood of recovery.
Conclusions
As psychotic experiences may be a marker of severity in CMD,
the benefits of identifying these in IAPT populations may also
apply to patients with milder experiences. Further investigation
of the consequential demands on service provision and how this
would affect clinical practice is recommended.
Keywords
Anxiety; at-risk mental state; common mental disorder; depres-
sion; psychotic experiences.
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Studies modelling the co-occurrence of common mental disorders
(CMD), such as anxiety and depression, and psychotic experiences
have revealed that such experiences measure severity of a unitary,
latent continuum of common mental distress1 and correlate with
increased comorbidity, suicidality and poorer treatment out-
comes.2–8 Psychotic experiences also predict propensity to seek treat-
ment from mental health services for persistent mental ill health.9
However, stringent referral thresholds prevent these individuals
accessing secondary mental healthcare services and they are therefore
managed in primary mental healthcare settings. In England, primary
mental healthcare for CMD is mainly delivered by the Improving
Access to Psychological Therapies (IAPT) programme (www.
england.nhs.uk/mental-health/adults/iapt/). The programme was
established to increase the access to National Institute for Health
and Care Excellence (NICE) recommended psychological treatments
within the National Health Service (NHS) across England.
The challenge in IAPT
Although commissioned to treat mild to moderate CMD, IAPT ser-
vices serve a clinical population with increasingly complex and
comorbid conditions.10–13 As psychotic experiences emerge in
more severe cases of CMD,1 we hypothesised in recent work that
a proportion of the IAPT population would experience psychotic
phenomena and, given the lack of specific treatment protocols for
addressing psychotic experiences, we also predicted that this
group would have poorer treatment outcomes.14 Using a cut-off
score of 1.47 on the 15-item Community Assessment of
Psychic Experiences-Positive (CAPE-P15) scale,15 a score
previously calibrated16 against the Comprehensive Assessment of
At-Risk Mental States (CAARMS),17 which identifies individuals
with at-risk mental states for psychosis, we identified psychotic
experiences in 30% of the IAPT case-load. This group of patients
began therapy with more severe depression and/or anxiety and
were significantly less likely to reach recovery by the end of
treatment.14 However, if we understand psychotic experiences,
depression and anxiety symptoms as manifestations of a
continuum of distress, arguably, a cut-off of 1.47 may not identify
all individuals with concurrent CMD and psychotic experiences in
IAPT services. It is possible that those experiencing intermittent
psychotic experiences will still have greater CMD severity and
poorer outcomes. Recently, we have shown that the sensitivity of
the CAPE-P15 can be increased (e.g. using a threshold of 1.30) to
offer a useful choice of cut-off values to identify more people with
psychotic experiences who may otherwise remain undetected but* Joint senior authors.
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may nonetheless not receive optimal treatment by the IAPT pro-
gramme in England.18
Aims
The current study explored this by replicating our earlier assessment
of the prevalence and impact of psychotic experiences among
patients treated in IAPT services14 using a more sensitive CAPE-
P15 cut-off score of 1.30. Specifically, we sought to determine the
increase in the proportion of the overall case-load with psychotic
experiences and compare the likelihood of recovery by the end of
treatment in IAPT services between patients with and without
comorbid lower-threshold psychotic experiences.
Method
Setting
The IAPT programme, which has transformed treatment of CMD
in England, began in 2008 with the purpose of substantially increas-
ing access to evidence-based psychological therapies for depression
and anxiety disorders.Widely deemed a success, the programme has
continued to expand over time to provide treatments to people with
long-term and medically unexplained symptoms, with NHS
England committing to covering 1.9 million adults aged 17–65
years annually by 2023–2024.19 Cognitive–behavioural therapy
(CBT) is the predominant approach adopted by these services,
although a wider range of treatments is offered, including counsel-
ling, interpersonal therapy and eye movement desensitisation and
reprocessing. Interventions are delivered via telephone, face to
face and, increasingly, online therapy in community settings and
can be accessed by people in England who are registered with a
general practitioner. Typically, the number sessions offered varies
between 8 and 20, depending on local commissioning guidelines,
over 3–4 months.
Measures
An integral part of the IAPT programme is rigorous performance
measurement and programme evaluation, and it therefore stipulates
a minimum data-set to record the clinical progress of each patient.
Patient-reported outcome measures of depression and anxiety are
obtained at baseline and at each subsequent treatment session,
ensuring that every patient has a clinical end-point even if treatment
is discontinued unexpectedly. The measures used include the
Patient Health Questionnaire (PHQ-9)20 and the Generalised
Anxiety Disorder questionnaire (GAD-7),21 and services store
these data using one of two patient management systems, PCMIS
(www.york.ac.uk/healthsciences/pc-mis) or iaptus (iaptus.co.uk).
This information is used to establish recovery from depression
and anxiety and, although several outcome indices are used, the
most commonly cited is the IAPT recovery index.22 This states
that a patient has entered recovery if they score above the clinical
cut-off on the PHQ-9 and/or GAD-7 at outset of treatment and
below the cut-off on both the PHQ-9 and GAD-7 post-treatment,
i.e. below 10 and 8 respectively. Nationally, 51% of patients acces-
sing IAPT recover,23 although outcomes vary significantly and are
influenced by factors including treatment fidelity, dose–response
effects and the complexity and severity of case-loads across ser-
vices.22–24
Our participating IAPT services also collected the current
CAPE-P15.15 The CAPE-P15 is a 15-item self-report measure of
the frequency and associated distress of psychotic experiences. It
provides a mean per-item score on two subscales (frequency of
psychotic experiences and associated distress), with higher scores
indicating a higher frequency of psychotic experiences and an
increased level of associated distress.25 We used a cut-off of 1.30
for both subscales to help identify patients with fewer and less
intense psychotic experiences than identified with the previously
recommended cut-off of 1.47.16
Sample
The analysis was conducted on patients receiving treatment from
IAPT services in three mental health trusts in England:
Cambridgeshire and Peterborough NHS Foundation Trust
(CPFT), Norfolk and Suffolk NHS Foundation Trust (NSFT) and
Sussex Partnership NHS Foundation Trust (SPFT). Each serves a
mixed urban and rural population and they together represent a
wide range of socioeconomic deprivation.
To replicate our previous analysis,14 data from all patients who
received IAPT treatment between the commencement and end of
CAPE-P15 collection (February to December 2018) were included.
Regardless of when each patient completed the CAPE-P15, recovery
data were obtained from their initial session up until their end-of-
care date.
All patients who were suitable for treatment under the IAPT
programme across the three participating mental health trusts
were eligible to complete the CAPE-P15 questionnaire. In two
trusts (CPFT and SPFT), the CAPE-P15 was offered to patients
during a treatment session or as a homework task. The third
trust (NSFT) used a digital portal to remotely collect routine
data, links to which were automatically sent out to patients by
the service. Patients were approached to complete a CAPE-P15
once during their course of treatment, at any time point deemed
appropriate by the therapist. It was accompanied by a short
explanation of the evaluation and instructions for completion.
Patients were informed that completing the CAPE-P15 was
voluntary.
This study was approved by and registered with the official NHS
Quality Improvement Programmes of all participating NHS mental
health trusts, with confirmation by the UK Health Research
Authority (hra.nhs.uk). Data analysis followed the guidelines estab-
lished by the UK Anonymisation Standard for Publishing Health
and Social Care Data (digital.nhs.uk).
Statistical analysis
We compared age, gender and ethnicity between patients who
scored 1.30 and above on the CAPE-P15 (hereafter referred to as
CAPE-positive), those who scored below 1.30 (CAPE-negative)
and those who did not complete a CAPE-P15 (no CAPE).
Continuous variables were compared using t-test and categorical
variables using chi-squared test (χ2). A P-value of less than 0.05
represents a statistically significant difference.
Prevalence and recovery rates are presented separately for
CAPE-positive and CAPE-negative individuals and includes
patients who had at least two sessions with the IAPT service and
at least one appointment after completing a CAPE-P15. To be
included in calculations of recovery rates, we stipulated that patients
should have been discharged from the service having had at least
one appointment after completing a CAPE-P15. Recovery was
determined using the recovery index.22
Multigroup growth modelling, with CAPE-positive and CAPE-
negative individuals comprising the groups, was carried out to esti-
mate improvement trajectories for each group. As essential infor-
mation regarding appointment number was not available at one
site (NSFT) a subsample of n = 1149 patients from CPFT and
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Results
In total, 2042 CAPE-P15 questionnaires were collected from 28 852
patients receiving IAPT treatment during the data collection period;
this was 7% of the case-load.
Participant sociodemographic characteristics
Table 1 presents a comparison of age, gender and ethnicity for
CAPE-positive versus CAPE-negative individuals. We also included
comparisons with individuals who did not complete a CAPE-P15, to
identify any potential bias as the sample was a proportion of the
case-load.
Age
The mean age of CAPE-positive individuals was 36.9 years (s.d. =
14.34) and it was 42.5 years (s.d. = 15.75) for CAPE-negative indivi-
duals; this difference was significant (t = 8.38, d.f. = 2034.3, P <
0.001).The mean age of participants who completed a CAPE-P15
was 39.8 years (s.d. = 15.34) and it was 39.2 years (s.d. = 15.25) for
participants who did not complete a CAPE-P15. There was no sig-
nificant difference in age between those who did and did not com-
plete a CAPE-P15 (t = 1.8127, d.f. = 2351.1, P = 0.07).
Gender
The percentage of women to men was higher in both the CAPE-
positive and CAPE-negative groups (67.6 and 70.4% respectively);
however, when CAPE-positive and CAPE-negative individuals
were compared, this gender difference was not significant
(χ2 = 1.82, d.f. = 1, P = 0.193). Although more women (68.9%) com-
pleted a CAPE-P15 than men (31%), this gender difference was not
significant when comparing participants who completed and did
not complete a CAPE-P15 (χ2 = 1.0206, d.f. = 1, P = 0.3124).
Ethnicity
Table 1 reveals that most people in this sample were White. Neither
the difference between CAPE-positive and CAPE-negative
individuals, nor the difference between those who did or did
not complete a CAPE-P15 was significant (χ2 = 10.1, d.f. = 6,
P = 0.122; χ2 = 12.225, d.f. = 6, P = 0.06 respectively).
Prevalence of psychotic experiences
Table 2 shows the total number of CAPE-P15 assessments com-
pleted by patients receiving treatment from IAPT services in each
of the three participating sites. The prevalence of CAPE-positive
individuals, as defined by a score of 1.30 or above, ranged from
43 to 52%.
Recovery rates
Table 3 compares the proportion of patients ending treatment in
recovery between CAPE-positive and CAPE-negative individuals.
Recovery rates for CAPE-negative individuals at all three sites fell
within the nationally reported range. The percentage of CAPE-posi-
tive individuals who had reached recovery by the end of treatment
was lower (26–50%) than the percentage of CAPE-negative indivi-
duals (55–69%).
Improvement trajectories
Figure 1 shows the mean improvement trajectories for CAPE-
positive and CAPE-negative individuals for both the PHQ-9 and
GAD-7. The initial CMD severity for CAPE-positive individuals
was higher than for CAPE-negative individuals on both measures.
CAPE-positive individuals began therapy with average scores of
17.5 and 15.5 on the PHQ-9 and GAD-7 respectively, compared
with CAPE-negative individuals, who entered treatment with
scores of approximately 13 and 12.
Although the improvement rates (trajectory slopes) were similar
for both groups, beginning treatment with more severe depression
Table 2 Prevalence of psychotic experiences among patients across three services delivering the Improving Access to Psychological Therapies (IAPT)
programme
CPFT (n = 590),
n (%)
NSFT (n = 1073),
n (%)
SPFT (n = 379),
n (%)
All sites (n = 2042),
n (%)
CAPE-positive 253 (42.9) 557 (51.9) 172 (45.4) 982 (48.1)
CAPE-negative 337 (57.1) 516 (48.1) 207 (54.6) 1060 (51.9)
CPFT, Cambridgeshire and Peterborough NHS Foundation Trust; NSFT, Norfolk and Suffolk NHS Foundation Trust; SPFT, Sussex Partnership NHS Foundation Trust; CAPE-positive, scored
≥1.30 on the Community Assessment of Psychic Experiences (CAPE-P15); CAPE-negative, scored <1.30 on the CAPE-P15.
Table 1 Comparison of age, gender and ethnicity for participants who
did and did not complete a Community Assessment of Psychic
Experiences (CAPE-P15) questionnaire






(n = 26 810)
Age, years
17 63 (6.4) 30 (2.8) 724 (2.7)
18–35 469 (47.8) 411 (38.8) 12 413 (46.3)
36–64 433 (44.1) 538 (50.8) 11 904 (44.4)
65+ 2 (1.7) 81 (7.6) 1769 (6.6)
Gender
Male 287 (29.2) 345 (32.5) 8633 (32.2)
Female 695 (70.8) 716 (67.5) 18 177 (67.8)
Ethnicity
Asian/Asian British 2 (1.8) 15 (1.4) 375 (1.4)
Black/African/Caribbean/Black British 1 (0.8) 8 (0.8) 188 (0.7)
Mixed/Multiple ethnic groups 2 (1.8) 8 (0.7) 375 (1.4)
Mixed other 1 (0.8) 2 (0.2) 107 (0.4)
Not stated/not known 86 (8.8) 68 (6.4) 1662 (6.2)
Other ethnic group 8 (0.8) 3 (0.3) 161 (0.6)
White 837 (85.2) 956 (90.2) 23, 968 (89.4)
Positive, scored ≥1.30 on the CAPE-P15; negative, scored <1.30 on the CAPE-P15; No
CAPE, did not complete a CAPE-P15.
Table 3 Recovery rates for patients with and without psychotic
experiences across three services delivering the Improving Access to
Psychological Therapies (IAPT) programme
Site CAPE-positive, n (%) CAPE-negative, n (%)
CPFT (n = 590) 253 (42.9) 337 (57.1)
NSFT (n = 1073) 557 (51.9) 516 (48.1)
SPFT (n = 379) 172 (45.4) 207 (54.6)
All sites (n = 2042) 982 (48.1) 1060 (51.6)
CAPE-positive, scored ≥1.30 on the Community Assessment of Psychic Experiences
(CAPE-P15); CAPE-negative, scored <1.30 on the CAPE-P15; CPFT, Cambridgeshire and
Peterborough NHS Foundation Trust; NSFT, Norfolk and Suffolk NHS Foundation Trust;
SPFT, Sussex Partnership NHS Foundation Trust.
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and anxiety meant that CAPE-positive individuals required many
more sessions to reach recovery thresholds (on average) compared
with CAPE-negative individuals. For both the PHQ-9 and GAD-7,
CAPE-positive individuals required on average 10 more sessions to
reach recovery than CAPE-negative individuals on both measures:
























































Fig. 1 Trajectories of improvement on the Patient Health Questionnaire (PHQ-9) and Generalised Anxiety Disorder questionnaire (GAD-7) for
participants with and without psychotic experiences. Positive, scored ≥1.30 on the Community Assessment of Psychic Experiences (CAPE-P15);
negative, scored <1.30 on the CAPE-P15.
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Discussion
Our study confirmed that a significant proportion of people using
primary mental healthcare services have comorbid CMD and
psychotic experiences, resulting in poorer treatment outcomes by
the end of therapy. Using a lower threshold score of 1.30 on the
CAPE-P15, this study found that approximately half of all patients
receiving IAPT treatment reported psychotic experiences. Only 36%
of this group reached recovery by the end of treatment, compared
with 64% without psychotic experiences. Although the overall
reduction in CAPE-P15 score was minimal, it was significant and
increased the identification of CAPE-positive individuals by 18%
compared with the previously used cut-off of 1.47.14
This study also confirmed our hypothesis that patients with
psychotic experiences would demonstrate more clinically severe
CMD than those without psychotic experiences. Analysis of recov-
ery trajectories showed that those with psychotic experiences
entered treatment with higher initial scores on measures of depres-
sion (PHQ-9) and anxiety (GAD-7) and required many more treat-
ment sessions, on average, to move from caseness to non-caseness.
This may appear inevitable, given that individuals with more severe
CMD require a larger reduction in scores to reach recovery than
those beginning treatment with scores pertaining to mild or moder-
ate CMD. IAPT services, however, are time limited and do not have
the capacity to offer unlimited therapy sessions, especially when you
consider that the more severe cases comprised half of the sample in
this study. Nationally, patients finally receive an average of seven
sessions of treatment.27
Attention should be directed at steepening the slope of the
improvement trajectory rather than increasing the number of ses-
sions. Here, we have shown that severity in CMD can be indexed
by the presence of psychotic experiences, but IAPT services do not
currently measure or provide interventions for those with these
symptoms in addition to depression and anxiety disorders.
Existing interventions that treat co-occurring CMD and psychotic
experiences are not currently included in IAPT protocols and
focus less on severe CMD and more on preventing transition to
first-episode psychosis, with a resultant decrease in depression
and anxiety.28 We suggest that a new conceptualisation of the
co-occurrence of CMD and psychotic experiences is necessary:
that psychotic experiences may dictate a continuum of CMD
rather than just a continuum of psychosis. This is especially true
for the population accessing primary mental healthcare services
specifically for the treatment of CMD and whose recovery is
assessed on the basis of a reduction of depression and anxiety
scores. Treatment therefore should be evidence based and focus
on these disorders. Moreover, these patients likely have treatment
goals closely aligned to their CMD. However, focusing on mood
disturbance alone oversimplifies the clinical reality and leaves
psychotic experiences untreated, potentially exacerbating depres-
sion and anxiety.
This study represents an important work stream of a wider,
innovative UK National Institute for Health Research (NIHR)
Programme Grant for Applied Research (TYPPEX), where we
propose that existing treatment protocols delivered by IAPT ser-
vices could be tailored for people with more severe CMD, indexed
by the presence of distressing psychotic experiences. Existing evi-
dence-based treatments for both CMD and at-risk mental states
for psychosis could be restructured to increase the potential for
recovery among these individuals. Identifying psychotic experi-
ences, understanding how they contribute to clinical outcomes
and reconfiguring familiar CBT-based techniques into existing
IAPT treatment protocols would provide a therapy tailored to
individual needs.
Limitations
This study provides practical evidence of the potential flexibility of
CAPE-P15 threshold scores to identify more people with less disab-
ling, but nonetheless debilitating psychotic experiences and facili-
tate access to more specific, tailored interventions in IAPT
services. Nevertheless, the interpretation of the findings must con-
sider the following limitations.
First, as CAPE-P15 completion was not mandated across our
sites (unlike the completion of the PHQ-9 and GAD-7), CAPE-P15
data were obtained for only a small proportion of the overall case-
load. In addition, selection bias was eliminated at only one site
(NSFT), where requests for completion of clinical measures were
automatically distributed to new patients via email. Conversely,
therapists in the other two sites could exercise discretion when
asking patients to complete a CAPE-P15 questionnaire. This could,
hypothetically, have inflated the prevalence of psychotic experiences
in these sites owing to the opportunity for therapists to select patients
withmore complex illness to facilitate an understanding of their pres-
entation. However, reassurance that this was not the case is found in
the following data: (a) the highest prevalence of psychotic experiences
was found in the site that automated CAPE-P15 collection (Table 3);
(b) recovery outcomes were similar across all sites; (c) sociodemo-
graphic variables did not differ between those who completed the
CAPE-P15 and those who did not across all sites.
Second, increasing the CAPE-P15’s sensitivity reduces its speci-
ficity. Lowering the threshold scores to 1.30 for frequency of psych-
otic experiences and associated distress not only increases the
probability of identifying more people with CMD who have psych-
otic experiences, but also increases the risk of false positives.
However, if the aim of identification is to deliver low-risk yet poten-
tially beneficial treatments, compromising specificity to increase
access to treatment may be valid.
Implications
Growing evidence suggests that psychotic experiences may be a
useful marker of severity in CMD. Consequently, the benefits of
identifying higher-threshold severe psychotic experiences in an
IAPT population14 may also apply to patients with milder psychotic
experiences. Future research should investigate the tolerability and
safety of such interventions and whether higher demands on service
provision could be met without affecting routine clinical practice.
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